PubMed:27292643 / 789-969 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T7","span":{"begin":0,"end":180},"obj":"Sentence"}],"text":"Faced with the selective pressure of oncogene withdrawal, Mad2-positive tumors have a higher frequency of developing persistent subclones that avoid remission and continue to grow."}

{"project":"LitCoin-entities","denotations":[{"id":"11381","span":{"begin":58,"end":62},"obj":"GeneOrGeneProduct"},{"id":"11382","span":{"begin":72,"end":78},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A18","pred":"db_id","subj":"11381","obj":"NCBIGene:56150"},{"id":"A19","pred":"db_id","subj":"11382","obj":"MESH:D009369"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Faced with the selective pressure of oncogene withdrawal, Mad2-positive tumors have a higher frequency of developing persistent subclones that avoid remission and continue to grow."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T21","span":{"begin":0,"end":5},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":37,"end":45},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":58,"end":62},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":72,"end":78},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":93,"end":102},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":117,"end":127},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":175,"end":179},"obj":"GeneOrGeneProduct"}],"text":"Faced with the selective pressure of oncogene withdrawal, Mad2-positive tumors have a higher frequency of developing persistent subclones that avoid remission and continue to grow."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T14","span":{"begin":37,"end":45},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":58,"end":62},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":93,"end":102},"obj":"GeneOrGeneProduct"}],"text":"Faced with the selective pressure of oncogene withdrawal, Mad2-positive tumors have a higher frequency of developing persistent subclones that avoid remission and continue to grow."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T11","span":{"begin":72,"end":78},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A11","pred":"originalLabel","subj":"T11","obj":"D009369"}],"text":"Faced with the selective pressure of oncogene withdrawal, Mad2-positive tumors have a higher frequency of developing persistent subclones that avoid remission and continue to grow."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T10","span":{"begin":58,"end":62},"obj":"GeneOrGeneProduct"}],"text":"Faced with the selective pressure of oncogene withdrawal, Mad2-positive tumors have a higher frequency of developing persistent subclones that avoid remission and continue to grow."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T14","span":{"begin":72,"end":78},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A14","pred":"ID:","subj":"T14","obj":"DISEASE"},{"id":"A15","pred":"ID:","subj":"T14","obj":"D009369"}],"text":"Faced with the selective pressure of oncogene withdrawal, Mad2-positive tumors have a higher frequency of developing persistent subclones that avoid remission and continue to grow."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T12","span":{"begin":72,"end":78},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A12","pred":"#label","subj":"T12","obj":"D009369"}],"text":"Faced with the selective pressure of oncogene withdrawal, Mad2-positive tumors have a higher frequency of developing persistent subclones that avoid remission and continue to grow."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T10","span":{"begin":58,"end":62},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":72,"end":78},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A12","pred":"#label","subj":"T12","obj":"D009369"}],"text":"Faced with the selective pressure of oncogene withdrawal, Mad2-positive tumors have a higher frequency of developing persistent subclones that avoid remission and continue to grow."}